Empros Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.emprospharma.com
Clinical Trials
8
Active:4
Completed:2
Trial Phases
2 Phases
Phase 1:6
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (75.0%)Phase 2
2 (25.0%)A Trial With EMP16 in Preparation for Late Phase Studies
Phase 2
Not yet recruiting
- Conditions
- Overweight or ObeseObesity and Overweight
- Interventions
- Drug: EMP16-02 120 mg orlistat/40 mg acarboseDietary Supplement: Vi-Siblin® SDietary Supplement: Maltodextrin
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Empros Pharma AB
- Target Recruit Count
- 39
- Registration Number
- NCT06993428
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Overweight or Obesity
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Empros Pharma AB
- Target Recruit Count
- 20
- Registration Number
- NCT06013163
- Locations
- 🇸🇪
CTC Clinical Trial Consultanta AB, Uppsala, Sweden
Study Exploring the Supportive Effect of Acarbose in Weight Management
Phase 2
Active, not recruiting
- Conditions
- Overweight or Obesity
- Interventions
- Drug: EMP16-120/40Drug: MR orlistat 120 mgDrug: Conventional orlistat 120 mg,Drug: EMP16-60/20Drug: Placebo
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Empros Pharma AB
- Target Recruit Count
- 320
- Registration Number
- NCT05934110
- Locations
- 🇸🇪
CTC Ebbepark, Linköping, Sweden
🇸🇪CTC Karolinska, Solna, Sweden
🇸🇪Clinical Trial Consultants (CTC), Uppsala,, Sweden
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
Phase 1
Completed
- Conditions
- Overweight or Obesity
- Interventions
- Drug: EMP16-02 120 mg orlistat/40 mg acarboseDrug: EMP16-02 150 mg orlistat/50 mg acarboseDrug: Placebo
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Empros Pharma AB
- Target Recruit Count
- 156
- Registration Number
- NCT04521751
- Locations
- 🇸🇪
Clinical Trial Consultants AB, Uppsala, Sweden
News
No news found